HIGHLY SELECTIVE ACTIVITY OF MDM2 INHIBITOR RG7112 AGAINST MDM2-AMPLIFIED/TP53 WILD-TYPE GLIOBLASTOMAS

被引：0

作者：

Verreault, Maite ^{[1
,2
,3
,4
]}

Levasseur, Camille ^{[1
,2
,3
,4
]}

Schmitt, Charlotte ^{[1
,2
,3
,4
]}

Guehennec, Jeremy ^{[1
,2
,3
,4
]}

Labussiere, Marianne ^{[1
,2
,3
,4
]}

Marie, Yannick ^{[1
,2
,3
,4
]}

Haidar, Sam ^{[5
,6
]}

Mokhtari, Karima ^{[1
,2
,3
,4
,7
]}

Hoang-Xuan, Khe ^{[1
,2
,3
,4
,7
]}

Sanson, Marc ^{[1
,2
,3
,4
,7
]}

Ligon, Keith ^{[5
,6
]}

Delattre, Jean-Yves ^{[1
,2
,3
,4
,7
]}

Idbaih, Ahmed ^{[1
,2
,3
,4
,7
]}

机构：

[1] INSERM, U1127, F-7501 Paris, France

[2] CNRS, UMR 7225, F-75013 Paris, France

[3] Univ Paris 06, Sorbonne Univ, UMR S 1127, F-75013 Paris, France

[4] ICM, F-750133 Paris, France

[5] Dana Farber Canc Inst, Ctr Mol Oncol Pathol, Dept Med Oncol, Boston, MA 02115 USA

[6] Brigham & Womens Hosp & Childrens, Div Neuropathol, Dept Pathol, Boston, MA USA

[7] Hop La Pitie Salpetriere, AP HP, Serv Neuropathol R Escourolle, Serv Neurol, F-75013 Paris, France

来源：

NEURO-ONCOLOGY | 2014年 / 16卷

关键词：

D O I：

10.1093/neuonc/nou255.59

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

ET-62

引用

页数：1

共 50 条

[31] Antitumor Activity of the Selective MDM2 Antagonist Nutlin-3 Against Chemoresistant Neuroblastoma With Wild-Type p53 [J].

Van Maerken, Tom ;

Ferdinande, Liesbeth ;

Taildeman, Jasmien ;

Lambertz, Irina ;

Yigit, Nurten ;

Vercruysse, Liesbeth ;

Rihani, Ali ;

Michaelis, Martin ;

Cinatl, Jindrich, Jr. ;

Cuvelier, Claude A. ;

Marine, Jean-Christophe ;

De Paepe, Anne ;

Bracke, Marc ;

Speleman, Frank ;

Vandesompele, Jo .

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2009, 101 (22) :1562-1574

[32] Pharmacodynamic Biomarkers in the Phase 1 Trial of RG7112, a Small-Molecule MDM2 Antagonist in Leukemia [J].

Andreeff, Michael ;

Kojima, Kensuke ;

Ruvolo, Vivian ;

Younes, Anas ;

Wei, Wei ;

Konopleva, Marina ;

Duvvuri, Seshagiri ;

Huang, Xuelin ;

Wu, Lin ;

Jukofsky, Lori ;

Vassilev, Lyubomir ;

Zhi, Jianguo ;

Geho, David ;

Nichols, Gwen .

BLOOD, 2011, 118 (21) :671-671

[33] Combined MEK/MDM2 inhibition demonstrates antitumor efficacy in TP53 wild-type thyroid and colorectal cancers with MAPK alterations [J].

Pairawan, Seyed ;

Akcakanat, Argun ;

Kopetz, Scott ;

Tapia, Coya ;

Zheng, Xiaofeng ;

Chen, Huiqin ;

Ha, Min Jin ;

Rizvi, Yasmeen ;

Holla, Vijaykumar ;

Wang, Jing ;

Evans, Kurt W. ;

Zhao, Ming ;

Busaidy, Naifa ;

Fang, Bingliang ;

Roth, Jack A. ;

Dumbrava, Ecaterina Ileana ;

Meric-Bernstam, Funda .

SCIENTIFIC REPORTS, 2022, 12 (01)

[34] TP53 wild-type/PPM1D mutant diffuse intrinsic pontine gliomas are sensitive to a MDM2 antagonist [J].

Cheng Xu ;

Heng Liu ;

Christopher J. Pirozzi ;

Lee H. Chen ;

Paula K. Greer ;

Bill H. Diplas ;

Liwei Zhang ;

Matthew S. Waitkus ;

Yiping He ;

Hai Yan .

Acta Neuropathologica Communications, 9

[35] Combined MEK/MDM2 inhibition demonstrates antitumor efficacy in TP53 wild-type thyroid and colorectal cancers with MAPK alterations [J].

Seyed Pairawan ;

Argun Akcakanat ;

Scott Kopetz ;

Coya Tapia ;

Xiaofeng Zheng ;

Huiqin Chen ;

Min Jin Ha ;

Yasmeen Rizvi ;

Vijaykumar Holla ;

Jing Wang ;

Kurt W. Evans ;

Ming Zhao ;

Naifa Busaidy ;

Bingliang Fang ;

Jack A. Roth ;

Ecaterina Ileana Dumbrava ;

Funda Meric-Bernstam .

Scientific Reports, 12

[36] TP53 wild-type/PPM1D mutant diffuse intrinsic pontine gliomas are sensitive to a MDM2 antagonist [J].

Xu, Cheng ;

Liu, Heng ;

Pirozzi, Christopher J. ;

Chen, Lee H. ;

Greer, Paula K. ;

Diplas, Bill H. ;

Zhang, Liwei ;

Waitkus, Matthew S. ;

He, Yiping ;

Yan, Hai .

ACTA NEUROPATHOLOGICA COMMUNICATIONS, 2021, 9 (01)

[37] A phase 2 basket study of the oral MDM2 inhibitor milademetan for MDM2-amplified advanced solid tumors (MANTRA-2) [J].

Dumbrava, Ecaterina E. ;

Chen, Christopher T. ;

Cote, Gregory M. ;

Hanna, Glenn J. ;

Stinchcombe, Thomas E. ;

Sumrall, Bradley ;

Wise-Draper, Trisha ;

Kanaan, Mohammed ;

Duffy, Steven ;

Sumey, Christopher ;

Cobb, Patrick ;

Shah, Naisargee ;

Zhang, Bo ;

Ku, Nora ;

Doebele, Robert C. ;

Gounder, Mrinal .

MOLECULAR CANCER THERAPEUTICS, 2023, 22 (12)

[38] Phase 1 Trial of ALRN-6924, a Dual Inhibitor of MDMX and MDM2, in Patients with Solid Tumors and Lymphomas Bearing Wild-type TP53 [J].

Saleh, Mansoor N. ;

Patel, Manish R. ;

Bauer, Todd M. ;

Goel, Sanjay ;

Falchook, Gerald S. ;

Shapiro, Geoffrey, I ;

Chung, Ki Y. ;

Infante, Jeffrey R. ;

Conry, Robert M. ;

Rabinowits, Guilherme ;

Hong, David S. ;

Wang, Judy S. ;

Steidl, Ulrich ;

Naik, Gurudatta ;

Guerlavais, Vincent ;

Vukovic, Vojislav ;

Annis, D. Allen ;

Aivado, Manuel ;

Meric-Bernstam, Funda .

CLINICAL CANCER RESEARCH, 2021, 27 (19) :5236-5247

[39] Correlation of TP53 and MDM2 genotypes with response to therapy in sarcoma [J].

Ohnstad, Hege O. ;

Castro, Russell ;

Sun, Jinchang ;

Heintz, Karen-Marie ;

Vassilev, Lyubomir T. ;

Bjerkehagen, Bodil ;

Kresse, Stine H. ;

Meza-Zepeda, Leonardo A. ;

Myklebost, Ola .

CANCER, 2013, 119 (05) :1013-1022

[40] A phase I study of MDM2 antagonist RG7112 in patients (pts) with relapsed/refractory solid tumors. [J].

Kurzrock, Razelle ;

Blay, Jean-Yves ;

Binh Bui Nguyen ;

Wagner, Andrew J. ;

Maki, Robert G. ;

Schwartz, Gary K. ;

Patnaik, Amita ;

Gore, Lia ;

Wu, Lin ;

Vassilev, Lyubomir T. ;

Ding, Michelle ;

Geho, David ;

Zhi, Jianguo ;

Middleton, Steven ;

Nichols, Gwen L. .

JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)

← 1 2 3 4 5 →